Genes and cholestasis
2001; Lippincott Williams & Wilkins; Volume: 34; Issue: 6 Linguagem: Inglês
10.1053/jhep.2001.29625
ISSN1527-3350
AutoresPeter L. M. Jansen, Michael Müller, Ekkehard Sturm,
Tópico(s)Liver Disease Diagnosis and Treatment
ResumoHepatologyVolume 34, Issue 6 p. 1067-1074 Concise ReviewFree Access Genes and cholestasis Peter L. M. Jansen, Corresponding Author Peter L. M. Jansen [email protected] Center for Liver, Digestive and Metabolic Diseases, University Hospital Groningen, Department of Gastroenterology and Hepatology; The Netherlands.Department of Gastroenterology and Hepatology, University Hospital Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands. fax: (31) 50-3619306===Search for more papers by this authorMichael Müller, Michael Müller Division of Nutrition, Metabolism and Genomics, University of Wageningen, Wageningen, The Netherlands.Search for more papers by this authorEkkehard Sturm, Ekkehard Sturm Department of Pediatrics, Groningen; University of Wageningen, Wageningen, The Netherlands.Search for more papers by this author Peter L. M. Jansen, Corresponding Author Peter L. M. Jansen [email protected] Center for Liver, Digestive and Metabolic Diseases, University Hospital Groningen, Department of Gastroenterology and Hepatology; The Netherlands.Department of Gastroenterology and Hepatology, University Hospital Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands. fax: (31) 50-3619306===Search for more papers by this authorMichael Müller, Michael Müller Division of Nutrition, Metabolism and Genomics, University of Wageningen, Wageningen, The Netherlands.Search for more papers by this authorEkkehard Sturm, Ekkehard Sturm Department of Pediatrics, Groningen; University of Wageningen, Wageningen, The Netherlands.Search for more papers by this author First published: 30 December 2003 https://doi.org/10.1053/jhep.2001.29625Citations: 68AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Hagenbuch B, Meier PJ. Molecular cloning, chromosomal localization, and functional characterization of a human liver Na+/bile acid cotransporter. J Clin Invest 1994; 93: 1326–1331.MEDLINE 2 Kouzuki H, Suzuki H, Stieger B, Meier PJ, Sugiyama Y. Characterization of the transport properties of organic anion transporting polypeptide 1 (oatp1) and Na(+)/taurocholate cotransporting polypeptide (Ntcp): comparative studies on the inhibitory effect of their possible substrates in hepatocytes and cDNA-transfected COS-7 cells. J Pharmacol Exp Ther 2000; 292: 505–511.MEDLINE 3 Cui Y, Konig J, Leier I, Buchholz U, Keppler D. Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem 2001; 276: 9626–9630.MEDLINE 4 Konig J, Cui Y, Nies AT, Keppler D. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol Gastrointest Liver Physiol 2000; 278: G156–G164.MEDLINE 5 Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, et al. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 2001; 120: 525–533.MEDLINE 6 Morton DH, Salen G, Batta AK, Shefer S, Tint GS, Belchis D, Shneider B, et al. Abnormal hepatic sinusoidal bile acid transport in an Amish kindred is not linked to FIC1 and is improved by ursodiol. Gastroenterology 2000; 119: 188–195.MEDLINE 7 Repa JJ, Mangelsdorf DJ. The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. Annu Rev Cell Dev Biol 2000; 16: 459–481.MEDLINE 8 Lu TT, Makishima M, Repa JJ, Schoonjans K, Kerr TA, Auwerx J, Mangelsdorf DJ. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol Cell 2000; 6: 507–515.MEDLINE 9 Goodwin B, Jones SA, Price RR, Watson MA, McKee DD, Moore LB, Galardi C, et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell 2000; 6: 517–526.MEDLINE 10 Denson LA, Sturm E, Echevarria W, Zimmerman TL, Makishima M, Mangelsdorf DJ, Karpen SJ. The orphan nuclear receptor, shp, mediates bile acid-induced inhibition of the rat bile acid transporter, ntcp. Gastroenterology 2001; 121: 140–147.MEDLINE 11 Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 2000; 102: 731–744.MEDLINE 12 Ananthanarayanan M, Balasubramanian N, Makishima M, Mangelsdorf DJ, Suchy FJ. Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J Biol Chem 2001; 276: 28857–28865.MEDLINE 13 Shih DQ, Bussen M, Sehayek E, Ananthanarayanan M, Shneider BL, Suchy FJ, Shefer S, et al. Hepatocyte nuclear factor-1alpha is an essential regulator of bile acid and plasma cholesterol metabolism. Nat Genet 2001; 27: 375–382.MEDLINE 14 Gartung C, Ananthanarayanan M, Rahman MA, Schuele S, Nundy S, Soroka CJ, Stolz A, et al. Down-regulation of expression and function of the rat liver Na+/bile acid cotransporter in extrahepatic cholestasis. Gastroenterology 1996; 110: 199–209.MEDLINE 15 Mukhopadhyay S, Ananthanarayanan M, Stieger B, Meier PJ, Suchy FJ, Anwer MS. Sodium taurocholate cotransporting polypeptide is a serine, threonine phosphoprotein and is dephosphorylated by cyclic adenosine monophosphate. Hepatology 1998; 28: 1629–1636.MEDLINE 16 Zollner G, Fickert P, Zenz R, Fuchsbichler A, Stumptner C, Kenner L, Ferenci P, et al. Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. Hepatology 2001; 33: 633–646.MEDLINE 17 Staudinger JL, Goodwin B, Jones SA, Hawkins-Brown D, MacKenzie KI, LaTour A, Liu Y, et al. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci U S A 2001; 98: 3369–3374.MEDLINE 18 Xie W, Radominska-Pandya A, Shi Y, Simon CM, Nelson MC, Ong ES, Waxman DJ, et al. An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids. Proc Natl Acad Sci U S A 2001; 98: 3375–3380.MEDLINE 19 Vos TA, Hooiveld GJ, Koning H, Childs S, Meijer DK, Moshage H, Jansen PL, et al. Up-regulation of the multidrug resistance genes, Mrp1 and Mdr1b, and down-regulation of the organic anion transporter, Mrp2, and the bile salt transporter, Spgp, in endotoxemic rat liver. Hepatology 1998; 28: 1637–1644.MEDLINE 20 Trauner M, Arrese M, Soroka CJ, Ananthanarayanan M, Koeppel TA, Schlosser SF, Suchy FJ, et al. The rat canalicular conjugate export pump (Mrp2) is down-regulated in intrahepatic and obstructive cholestasis. Gastroenterology 1997; 113: 255–264.MEDLINE 21 Lee JM, Trauner M, Soroka CJ, Stieger B, Meier PJ, Boyer JL. Expression of the bile salt export pump is maintained after chronic cholestasis in the rat. Gastroenterology 2000; 118: 163–172.MEDLINE 22 Ogawa K, Suzuki H, Hirohashi T, Ishikawa T, Meier PJ, Hirose K, Akizawa T, et al. Characterization of inducible nature of MRP3 in rat liver. Am J Physiol Gastrointest Liver Physiol 2000; 278: G438–G446.MEDLINE 23 Soroka CJ, Lee JM, Azzaroli F, Boyer JL. Cellular localization and up-regulation of multidrug resistance-associated protein 3 in hepatocytes and cholangiocytes during obstructive cholestasis in rat liver. Hepatology 2001; 33: 783–791.MEDLINE 24 Hirohashi T, Suzuki H, Sugiyama Y. Characterization of the transport properties of cloned rat multidrug resistance-associated protein 3 (MRP3). J Biol Chem 1999; 274: 15181–15185.MEDLINE 25 Hirohashi T, Suzuki H, Takikawa H, Sugiyama Y. ATP-dependent transport of bile salts by rat multidrug resistance-associated protein 3 (Mrp3). J Biol Chem 2000; 275: 2905–2910.MEDLINE 26 Clayton RJ, Iber FL, Ruebner BH, McKusick VA. Byler disease. Fatal familial intrahepatic cholestasis in an Amish kindred. Am J Dis Child 1969; 117: 112–124.MEDLINE 27 Carlton VE, Knisely AS, Freimer NB. Mapping of a locus for progressive familial intrahepatic cholestasis (Byler disease) to 18q21-q22, the benign recurrent intrahepatic cholestasis region. Hum Mol Genet 1995; 4: 1049–1053.MEDLINE 28 Bull LN, Carlton VE, Stricker NL, Baharloo S, DeYoung JA, Freimer NB, Magid MS, et al. Genetic and morphological findings in progressive familial intrahepatic cholestasis (Byler disease [PFIC-1] and Byler syndrome): evidence for heterogeneity. Hepatology 1997; 26: 155–164.MEDLINE 29 Oshima T, Ikeda K, Takasaka T. Sensorineural hearing loss associated with Byler disease. Tohoku J Exp Med 1999; 187: 83–88.MEDLINE 30 Alonso EM, Snover DC, Montag A, Freese DK, Whitington PF. Histologic pathology of the liver in progressive familial intrahepatic cholestasis. J Pediatr Gastroenterol Nutr 1994; 18: 128–133.MEDLINE 31 Tygstrup N, Steig BA, Juijn JA, Bull LN, Houwen RH. Recurrent familial intrahepatic cholestasis in the Faeroe Islands. Phenotypic heterogeneity but genetic homogeneity. Hepatology 1999; 29: 506–508.MEDLINE 32 Bull LN, Juijn JA, Liao M, van Eijk MJ, Sinke RJ, Stricker NL, DeYoung JA, et al. Fine-resolution mapping by haplotype evaluation: the examples of PFIC1 and BRIC. Hum Genet 1999; 104: 241–248.MEDLINE 33 Bull LN, van Eijk MJ, Pawlikowska L, DeYoung JA, Juijn JA, Liao M, Klomp LW, et al. A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis. Nat Genet 1998; 18: 219–224.MEDLINE 34 Floreani A, Molaro M, Mottes M, Sangalli A, Baragiotta A, Roda A, Naccarato R, et al. Autosomal dominant benign recurrent intrahepatic cholestasis (BRIC) unlinked to 18q21 and 2q24. Am J Med Genet 2000; 95: 450–453.MEDLINE 35 Crosignani A, Podda M, Bertolini E, Battezzati PM, Zuin M, Setchell KD. Failure of ursodeoxycholic acid to prevent a cholestatic episode in a patient with benign recurrent intrahepatic cholestasis: a study of bile acid metabolism. Hepatology 1991; 13: 1076–1083.MEDLINE 36 Brenard R, Geubel AP, Benhamou JP. Benign recurrent intrahepatic cholestasis. A report of 26 cases. J Clin Gastroenterol 1989; 11: 546–551.MEDLINE 37 Cancado EL, Leitao RM, Carrilho FJ, Laudanna AA. Unexpected clinical remission of cholestasis after rifampicin therapy in patients with normal or slightly increased levels of gamma-glutamyl transpeptidase. Am J Gastroenterol 1998; 93: 1510–1517.MEDLINE 38 Balsells F, Wyllie R, Steffen R, Kay M. Benign recurrent intrahepatic cholestasis: improvement of pruritus and shortening of the symptomatic phase with rifampin therapy: a case report. Clin Pediatr (Phila) 1997; 36: 483–485.MEDLINE 39 Arnell H, Nemeth A, Anneren G, Dahl N. Progressive familial intrahepatic cholestasis (PFIC): evidence for genetic heterogeneity by exclusion of linkage to chromosome 18q21-q22. Hum Genet 1997; 100: 378–381.MEDLINE 40 Strautnieks SS, Kagalwalla AF, Tanner MS, Gardiner RM, Thompson RJ. Locus heterogeneity in progressive familial intrahepatic cholestasis. J Med Genet 1996; 33: 833–836.MEDLINE 41 Strautnieks SS, Bull LN, Knisely AS, Kocoshis SA, Dahl N, Arnell H, Sokal E, et al. A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat Genet 1998; 20: 233–238.MEDLINE 42 Jansen PL, Strautnieks SS, Jacquemin E, Hadchouel M, Sokal EM, Hooiveld GJ, Koning JH, et al. Hepatocanalicular bile salt export pump deficiency in patients with progressive familial intrahepatic cholestasis. Gastroenterology 1999; 117: 1370–1379.MEDLINE 43 Alonso EM, Snover DC, Montag A, Freese DK, Whitington PF. Histologic pathology of the liver in progressive familial intrahepatic cholestasis. J Pediatr Gastroenterol Nutr 1994; 18: 128–133.MEDLINE 44 Wang R, Salem M, Yousef IM, Tuchweber B, Lam P, Childs SJ, Helgason CD, et al. Targeted inactivation of sister of P-glycoprotein gene (spgp) in mice results in nonprogressive but persistent intrahepatic cholestasis. Proc Natl Acad Sci U S A 2001; 98: 2011–2016.MEDLINE 45 Deleuze JF, Jacquemin E, Dubuisson C, Cresteil D, Dumont M, Erlinger S, Bernard O, et al. Defect of multidrug-resistance 3 gene expression in a subtype of progressive familial intrahepatic cholestasis. Hepatology 1996; 23: 904–908.MEDLINE 46 De Vree JM, Jacquemin E, Sturm E, Cresteil D, Bosma PJ, Aten J, Deleuze JF, et al. Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis. Proc Natl Acad Sci U S A 1998; 95: 282–287.MEDLINE 47 Jacquemin E, De Vree JM, Cresteil D, Sokal EM, Sturm E, Dumont M, Scheffer GL, et al. The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood. Gastroenterology 2001; 120: 1448–1458.MEDLINE 48 Smit JJ, Schinkel AH, Oude Elferink RP, Groen AK, Wagenaar E, van Deemter L, Mol CA, et al. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 1993; 75: 451–462.MEDLINE 49 Jacquemin E, Cresteil D, Manouvrier S, Boute O, Hadchouel M. Heterozygous non-sense mutation of the MDR3 gene in familial intrahepatic cholestasis of pregnancy. Lancet 1999; 353: 210–211.MEDLINE 50 Jacquemin E. Progressive familial intrahepatic cholestasis. J Gastroenterol Hepatol 1999; 14: 594–599.MEDLINE 51 Emond JC, Whitington PF. Selective surgical management of progressive familial intrahepatic cholestasis (Byler's disease). J Pediatr Surg 1995; 30: 1635–1641.MEDLINE 52 Whitington PF, Whitington GL. Partial external diversion of bile for the treatment of intractable pruritus associated with intrahepatic cholestasis. Gastroenterology 1988; 95: 130–136.MEDLINE 53 Melter M, Rodeck B, Kardorff R, Hoyer PF, Petersen C, Ballauff A. Progressive familial intrahepatic cholestasis: partial biliary diversion normalizes serum lipids and improves growth in noncirrhotic patients. Am J Gastroenterol 2000; 95: 3522–3528.MEDLINE 54 Soubrane O, Gauthier F, DeVictor D, Bernard O, Valayer J, Houssin D, Chapuis Y. Orthotopic liver transplantation for Byler disease. Transplantation 1990; 50: 804–806.MEDLINE 55 Sturm E, Drews AL, Rogiers X, Schafer E, Malago M, Broelsch CE, Burdelski M. Case report: recurrence of progressive familial intrahepatic cholestasis (PFIC) in a living related liver transplant [Abstract]. Hepatology 1995; 22: 207A. 56 Clayton PT, Leonard JV, Lawson AM, Setchell KD, Andersson S, Egestad B, Sjovall J. Familial giant cell hepatitis associated with synthesis of 3 beta, 7 alpha-dihydroxy-and 3 beta,7 alpha, 12 alpha-trihydroxy-5-cholenoic acids. J Clin Invest 1987; 79: 1031–1038.MEDLINE 57 Setchell KD, Schwarz M, O'Connell NC, Lund EG, Davis DL, Lathe R, Thompson HR, et al. Identification of a new inborn error in bile acid synthesis: mutation of the oxysterol 7alpha-hydroxylase gene causes severe neonatal liver disease. J Clin Invest 1998; 102: 1690–1703.MEDLINE 58 Setchell KD, Suchy FJ, Welsh MB, Zimmer-Nechemias L, Heubi J, Balistreri WF. Delta 4-3-oxosteroid 5 beta-reductase deficiency described in identical twins with neonatal hepatitis. a new inborn error in bile acid synthesis. J Clin Invest 1988; 82: 2148–2157.MEDLINE 59 Stieger B, Zhang J, O'Neill B, Sjovall J, Meier PJ. Differential interaction of bile acids from patients with inborn errors of bile acid synthesis with hepatocellular bile acid transporters. Eur J Biochem 1997; 244: 39–44.MEDLINE 60 Dixon PH, Weerasekera N, Linton KJ, Donaldson O, Chambers J, Egginton E, Weaver J, et al. Heterozygous MDR3 missense mutation associated with intrahepatic cholestasis of pregnancy: evidence for a defect in protein trafficking. Hum Mol Genet 2000; 9: 1209–1217.MEDLINE 61 de Pagter AG, Berge Henegouwen GP, Bokkel Huinink JA, Brandt KH. Familial benign recurrent intrahepatic cholestasis. Interrelation with intrahepatic cholestasis of pregnancy and from oral contraceptives? Gastroenterology 1976; 71: 202–207.MEDLINE 62 Mazzella G, Nicola R, Francesco A, Patrizia S, Luciano B, Anna M, Giuliana S, et al. Ursodeoxycholic acid administration in patients with cholestasis of pregnancy: effects on primary bile acids in babies and mothers. Hepatology 2001; 33: 504–508.MEDLINE 63 Berkane N, Cocheton JJ, Brehier D, Merviel P, Wolf C, Lefevre G, Uzan S. Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy. A retrospective study of 19 cases. Acta Obstet Gynecol Scand 2000; 79: 941–946.MEDLINE 64 Palma J, Reyes H, Ribalta J, Hernandez I, Sandoval L, Almuna R, Liepins J, et al. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. J Hepatol 1997; 27: 1022–1028.MEDLINE 65 Rosmorduc O, Hermelin B, Poupon R. MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis. Gastroenterology 2001; 120: 1459–1467.MEDLINE 66 Ananthanarayanan M, Balasubramanian NV, Makishima M, Mangelsdorf DJ, Suchy FJ. Human bile salt export pump (BSEP) promoter is transactivated by the farnesoid X receptor/bile acid receptor (FXR/BAR). J Biol Chem 2001; 276: 28857–28865.MEDLINE 67 Laffitte BA, Kast HR, Nguyen CM, Zavacki AM, Moore DD, Edwards PA. Identification of the DNA binding specificity and potential target genes for the farnesoid X-activated receptor. J Biol Chem 2000; 275: 10638–10647.MEDLINE 68 Chiang JY, Kimmel R, Weinberger C, Stroup D. Farnesoid X receptor responds to bile acids and represses cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription. J Biol Chem 2000; 275: 10918–10924.MEDLINE 69 Harris HW, Jr., Carpenter TO, Shanley P, Rosen S, Levey RH, Harmon WE. Progressive tubulointerstitial renal disease in infancy with associated hepatic abnormalities. Am J Med 1986; 81: 169–176.MEDLINE 70 Neuhaus TJ, Stallmach T, Leumann E, Altorfer J, Braegger CP. Familial progressive tubulo-interstitial nephropathy and cholestatic liver disease—a newly recognized entity? Eur J Pediatr 1997; 156: 723–726.MEDLINE 71 Popovic-Rolovic M, Kostic M, Sindjic M, Jovanovic O, Peco-Antic A, Kruscic D. Progressive tubulointerstitial nephritis and chronic cholestatic liver disease. Pediatr Nephrol 1993; 7: 396–400.MEDLINE 72 Quigley EM, LaRusso NF, Ludwig J, MacSween RN, Birnie GG, Watkinson G. Familial occurrence of primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1983; 85: 1160–1165.MEDLINE 73 Debray D, Pariente D, Urvoas E, Hadchouel M, Bernard O. Sclerosing cholangitis in children. J Pediatr 1994; 124: 49–56.MEDLINE 74 Debray D, Pariente D, Urvoas E, Hadchouel M, Bernard O. Sclerosing cholangitis of neoantal onset. J Pediatr Gastroenterol Nutr 1994; 17: 463. 75 Isoyama K, Yamada K, Ishikawa K, Sanada Y. Coincidental cases of primary sclerosing cholangitis and biliary atresia in siblings? Acta Paediatr 1995; 84: 1444–1446.MEDLINE 76 Muller T, Schafer H, Rodeck B, Haupt G, Koch H, Bosse H, Welling P, et al. Familial clustering of infantile cirrhosis in Northern Germany: a clue to the etiology of idiopathic copper toxicosis. J Pediatr 1999; 135: 189–196.MEDLINE 77 Muller T, Feichtinger H, Berger H, Muller W. Endemic Tyrolean infantile cirrhosis: an ecogenetic disorder. Lancet 1996; 347: 877–880.MEDLINE 78 Wijmenga C, Muller T, Murli IS, Brunt T, Feichtinger H, Schonitzer D, Houwen RH, et al. Endemic Tyrolean infantile cirrhosis is not an allelic variant of Wilson's disease. Eur J Hum Genet 1998; 6: 624–628.MEDLINE 79 Bhagwat AG. Indian childhood cirrhosis (ICC): a complete classified review (1887-1980). Indian Pediatr 1980; 17: 581–585.MEDLINE 80 Gupta V, Mudgil A, Srivastava A, Rathi AK. Serum gamma glutamyl transferase in Indian childhood cirrhosis. J Indian Med Assoc 1983; 80: 6–7.MEDLINE 81 Tanner MS, Portmann B, Mowat AP, Williams R, Pandit AN, Mills CF, Bremner I. Increased hepatic copper concentration in Indian childhood cirrhosis. Lancet 1979; 1: 1203–1205.MEDLINE 82 Popper H, Goldfischer S, Sternlieb I, Nayak NC, Madhavan TV. Cytoplasmic copper and its toxic effects. Studies in Indian childhood cirrhosis. Lancet 1979; 1: 1205–1208.MEDLINE 83 Phillips MJ, Ackerley CA, Superina RA, Roberts EA, Filler RM, Levy GA. Excess zinc associated with severe progressive cholestasis in Cree and Ojibwa-Cree children. Lancet 1996; 347: 866–868.MEDLINE 84 Knisely AS. Progressive familial intrahepatic cholestasis: a personal perspective. Pediatr Dev Pathol 2000; 3: 113–125.MEDLINE 85 Weber AM, Tuchweber B, Yousef I, Brochu P, Turgeon C, Gabbiani G, Marin CL, et al. Severe familial cholestasis in North American Indian children: a clinical model of microfilament dysfunction? Gastroenterology 1981; 81: 653–662.MEDLINE 86 Holve S, Hu D, Shub M, Tyson RW, Sokol RJ. Liver disease in Navajo neuropathy. J Pediatr 1999; 135: 482–493.MEDLINE 87 Di Rocco M, Callea F, Pollice B, Faraci M, Campiani F, Borrone C. Arthrogryposis, renal dysfunction and cholestasis syndrome: report of five patients from three Italian families. Eur J Pediatr 1995; 154: 835–839.MEDLINE 88 Aagenaes O. Hereditary cholestasis with lymphoedema (Aagenaes syndrome, cholestasis-lymphoedema syndrome). New cases and follow-up from infancy to adult age. Scand J Gastroenterol 1998; 33: 335–345.MEDLINE 89 Bull LN, Roche E, Song EJ, Pedersen J, Knisely4 AS, Der Hagen CB, Eiklid K. Mapping of the locus for cholestasis-lymphedema syndrome (Aagenaes syndrome) to a 6.6-cM interval on chromosome 15q. Am J Hum Genet 2000; 67: 994–999.MEDLINE Citing Literature Volume34, Issue6December 2001Pages 1067-1074 ReferencesRelatedInformation
Referência(s)